LONDON (SHARECAST) - Vaccine maker Acambis said Novartis has agreed to pay it $19m in cash to settle a dispute related to the ARILVAX(TM) yellow fever vaccine.
“Under the settlement agreement, Novartis will pay $19m (c.£10m) in September 2006 to compensate Acambis,” said the group.
Novartis has also granted Acambis an exclusive option to negotiate a licence for the worldwide rights of the product..
Acambis also announced that it was encouraged by the Phase 2 clinical trial of its vaccine against West Nile virus, ChimeriVax-West Nile.
‘We are very encouraged by these results, especially the high immune response generated in subjects by just a single dose of ChimeriVax-West Nile,” said the group.
